International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment, Ann Oncol, vol.22, pp.515-523, 2011. ,
First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients, Ann Oncol, vol.24, pp.2773-2780, 2013. ,
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2negative primary breast cancer (GBG 44-GeparQuinto), Ann Oncol, vol.25, pp.2363-2372, 2014. ,
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial, Lancet Oncol, vol.16, pp.1037-1048, 2015. ,
Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer, Clin Cancer Res, vol.22, pp.2583-2593, 2016. ,
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial, Clin Cancer Res, vol.14, pp.7004-7010, 2008. ,
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial, Clin Cancer Res, vol.16, pp.2634-2645, 2010. ,
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study, Lancet Oncol, vol.13, pp.375-384, 2012. ,
Circulating tumor cells in newly diagnosed inflammatory breast cancer, Breast Cancer Res, vol.17, issue.2, 2015. ,
Pathological response and circulating tumor cell count identifies treated HER2þ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data, Clin Cancer Res, vol.21, pp.1298-1304, 2015. ,
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study, Lancet Oncol, vol.17, pp.600-611, 2016. ,
Circulating tumor cells and recurrence after primary systemic therapy in stage III inflammatory breast cancer, J Natl Cancer Inst, vol.107, 2015. ,
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy, Ann Oncol, vol.21, pp.1765-1771, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00508113
High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients, Ann Oncol, vol.23, pp.618-624, 2012. ,
Changes in circulating tumor and endothelial cells in peripheral blood of patients treated in the neoadjuvant chemotherapy plus targeted treatment breast cancer study "GeparQuinto, Cancer Res, vol.70, pp.4-06, 2010. ,
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia, Proc Natl Acad Sci U S A, vol.109, pp.2784-2789, 2012. ,
Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells, Breast Cancer Res, vol.14, p.15, 2012. ,
Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero, Ann Oncol, vol.22, pp.1929-1930, 2011. ,
Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells, Chin J Cancer Res, vol.27, pp.491-496, 2015. ,
Circulating tumor cells in breast cancer, Mol Oncol, vol.10, pp.418-430, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-00749450
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy, Oncotarget, vol.6, pp.13506-13519, 2015. ,
Frequent expression of PD-L1 on circulating breast cancer cells, Mol Oncol, vol.9, pp.1773-1782, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01162382